AI Article Synopsis
- This study focused on patients with luminal metastatic breast cancer experiencing visceral crisis, analyzing their treatment in a university medical oncology department from 2013 to 2016.
- A total of 35 patients were studied, showing that those in visceral crisis had poorer health and organ function, with 65% receiving chemotherapy but no significant improvement in outcomes.
- The average time from visceral crisis to death was about 4.7 weeks, highlighting the necessity for better understanding and treatment strategies for patients in this condition.
Article Abstract
Background: Patients with visceral crisis from luminal metastatic breast cancer (mBC) are often treated with palliative chemotherapy. No studies have analyzed the aggressiveness of the care in visceral crisis from luminal mBC patients. The objective of this study was to assess practices in this setting in a university medical oncology department.
Methods: This retrospective study included all patients who were managed for luminal mBC between January 2013 and April 2016. The analysis focused on the characteristics of the patients, the modalities of cancer treatment and delays between visceral crisis and death.
Results: Thirty-five patients pre-treated with two hormonal therapy lines were enrolled retrospectively. Worse performance status and a higher proportion of severe organ dysfunction for luminal mBC were observed among patients with visceral crisis. Sixty-five percent of patients received cytotoxic treatment. One cycle of chemotherapy was administrated in the majority of patients. Palliative care was performed in 35% of patients. Chemotherapy did not have any significant effect on patient outcome in the present study. The mean time between visceral crisis and death was 4.7 weeks (standard deviation = 1.9).
Conclusion: Our study showed that visceral crisis in patients with luminal mBC is a complex problem. We need more comprehension of molecular pathogenesis to visceral crisis disease to propose efficacious treatments for these patients and to identify subgroup of patients who need chemotherapy followed by maintenance endocrine therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650006 | PMC |
| http://dx.doi.org/10.14740/wjon1043w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis.
Gut Liver
January 2025
Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Background/aims: The incidence of steatotic liver disease (SLD) is increasing across all age groups as the incidence of obesity increases worldwide. The existing noninvasive prediction models for SLD require laboratory tests or imaging and perform poorly in the early diagnosis of infrequently screened populations such as young adults and individuals with healthcare disparities. We developed a machine learning-based point-of-care prediction model for SLD that is readily available to the broader population with the aim of facilitating early detection and timely intervention and ultimately reducing the burden of SLD.
View Article and Find Full Text PDF[Telemedicine and AI-supported diagnostics in the daily routine of visceral medicine].
Chirurgie (Heidelb)
January 2025
Universitätsklinik für Viszeralchirurgie - Pius-Hospital Oldenburg, Universitätsmedizin Oldenburg, Oldenburg, Deutschland.
Advances in telemedicine, exemplified by augmented reality (AR) and virtual reality (VR), are rapidly progressing. For instance, AR available over long distances has already been successfully utilized in crisis intervention, such as in war zones. The potential of telemedicine also appears promising in structurally weak areas or in the involvement of experts in emergency situations.
View Article and Find Full Text PDFPrevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis.
Front Public Health
December 2024
Department of Environmental Health, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
Introduction: Visceral Leishmaniasis, also known as kala-azar, is a potentially fatal, neglected tropical disease caused by the protozoan parasite and transmitted through infected sandflies. It is one of the major global public health problems and contributors to economic crisis among people. Though different studies investigated human visceral leishmaniasis in Eastern Africa, the findings were inconsistent and inconclusive enough, and there is no representative data on this devastating public health concern.
View Article and Find Full Text PDFFirst-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report.
J Med Case Rep
December 2024
Hematology Medical Oncology Division, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital Semarang, Semarang, Indonesia.
Article Synopsis
- - Metastatic breast cancer, particularly disseminated carcinomatosis of bone marrow (DCBM), is rare and poses a serious threat to life, with a focus on managing symptoms and improving quality of life rather than finding a cure.
- - A case study is presented of a 36-year-old woman diagnosed with luminal breast cancer who experienced severe symptoms due to DCBM; she was initially treated with tamoxifen but later switched to letrozole, ribociclib, and leuprorelin due to side effects.
- - The treatment adjustment led to significant improvements in her blood markers, symptoms, and overall quality of life, suggesting that combining endocrine therapy with a CDK4/6 inhibitor could be an effective
Evaluation of CDK4/6 inhibitors in first-line in symptomatic and asymptomatic patients with metastatic breast cancer.
Future Oncol
December 2024
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital Ankara, Ankara, Turkey.
Background: This study aimed to compare the efficacy of CDK4/6 inhibitors plus endocrine therapy in two groups of patients with HR-positive/HER2-negative metastatic breast cancer: those with symptomatic, high tumor burden disease and those with asymptomatic disease.
Design And Methods: This retrospective study included 193 patients who received either ribociclib or palbociclib in combination with first-line ET. Patients were divided into symptomatic and asymptomatic groups and compared regarding baseline characteristics and progression-free survivals (PFS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!